Since its establishment in 2000, the Ohio Valley Node (OVN) has been one of the most productive of NIDA's Clinical Trials Network (CTN) nodes, both in leading and participating in multi-site trials. In this application the OVN has been expanded to be a node of networks: the Ohio Valley Node-Network (OVNN). The OVNN includes eight original OVN sites, which are located in 6 states and treat more than 225,000 patients per year; and three additional practice based research networks (PBRNs). Two are state-wide primary care PBRNs, the Collaborative Ohio Inquiry Network (COIN) and the Wisconsin Research and Education Network (WREN), which, combined, include more than 350 practices and treat more than 4 million patients per year. The third is a state-wide pharmacy PBRN in Indiana, which includes 168 pharmacies that fill 1.5 million prescriptions annually. These Midwestern sites and partnerships will contribute needed diversity to CTN clinical trials. The OVNN Research Core is the driving force of the OVNN and is led by Dr. Winhusen, one of the foremost experts in conducting multi-site addiction clinical trials in clinical practice settings. The OVNN co-investigators include experts in primary care (Elder), emergency medicine (Lyons), and pediatric emergency medicine (Grupp- Phelan) practice-based research. The 7 members of the OVN research-implementation team bring 72 years of combined experience conducting CTN clinical trials. A primary goal of the application is to conduct the research needed to inform clinical practice guidelines for effective substance use disorder (SUD) prevention and treatment in general medical care settings, which are largely lacking but increasingly needed, with a specific focus on research to address the opioid abuse epidemic. Our proposed research agenda includes pragmatic clinical trials testing interventions to predict, prevent, and respond to opioid misuse in primary care; to reduce the reoccurrence of opioid overdose by linking patients treated for an overdose in emergency medicine departments to SUD treatment through a novel peer-based intervention; and to reduce the transmission of HIV and HCV through pharmacy-based testing for buprenorphine-treated patients.

Public Health Relevance

Since its establishment in 2000, the Ohio Valley Node (OVN) has been one of the most productive of NIDA's Clinical Trials Network (CTN) nodes, both in leading and participating in multi-site trials. The wealth of experience and expertise gained over the past 14 years has been used to cultivate collaborations with other research networks to form the Ohio Valley Node-Network (OVNN). Our primary goal is to conduct the research needed to inform clinical practice guidelines for effective substance use disorder prevention and treatment in general medical care settings, which are largely lacking but increasingly needed, with a specific focus on research to address the opioid abuse epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1DA013732-17
Application #
9115115
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Dobbins, Ronald
Project Start
2000-09-30
Project End
2020-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
17
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Psychiatry
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Luo, Sean X; Wall, Melanie; Covey, Lirio et al. (2018) Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. Am J Drug Alcohol Abuse 44:653-659
Campbell, Aimee N C; Barbosa-Leiker, Celestina; Hatch-Maillette, Mary et al. (2018) Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict 27:465-470
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Aharonovich, Efrat; Campbell, Aimee N C; Shulman, Matisyahu et al. (2018) Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. J Addict Med 12:99-106
Korthuis, Philip T; Lum, Paula J; Vergara-Rodriguez, Pamela et al. (2017) Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction 112:1036-1044
Osterman, Robin; Lewis, Daniel; Winhusen, Theresa (2017) Efficacy of motivational enhancement therapy to decrease alcohol and illicit-drug use in pregnant substance users reporting baseline alcohol use. J Subst Abuse Treat 77:150-155
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Montgomery, LaTrice; Carroll, Kathleen M (2017) Comparable efficacy of behavioral and pharmacological treatments among African American and White cocaine users. J Ethn Subst Abuse 16:445-459
Gray, Kevin M; Sonne, Susan C; McClure, Erin A et al. (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 177:249-257
Winhusen, Theresa; Lewis, Daniel (2017) Cigarette smoking in pregnant substance users: Association with substance use and desire to quit. J Addict Dis 36:88-91

Showing the most recent 10 out of 21 publications